What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research
Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.